Screener
Allogene Therapeutics ALLO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 70,023 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 |
| Total assets | $395,958 | $415,905 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,933 | $4,270 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's deferred tax assets and other non-current assets?
- Allogene Therapeutics (ALLO) reported deferred tax assets and other non-current assets of $3.53M in Q1 2026.
- How has Allogene Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Allogene Therapeutics's deferred tax assets and other non-current assets increased by 85.8% year-over-year, from $1.9M to $3.53M.
- What is the long-term trend for Allogene Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's deferred tax assets and other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $5.17M to $3.62M.
Ask your AI about Allogene Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude